1
|
Diaz de la Guardia R, González-Silva L, López-Millán B, Rodríguez-Sevilla JJ, Baroni ML, Bueno C, Anguita E, Vives S, Palomo L, Lapillonne H, Varela I, Menendez P. Bone Marrow Clonogenic Myeloid Progenitors from NPM1-Mutated AML Patients Do Not Harbor the NPM1 Mutation: Implication for the Cell-Of-Origin of NPM1+ AML. Genes (Basel) 2020; 11:genes11010073. [PMID: 31936647 PMCID: PMC7017102 DOI: 10.3390/genes11010073] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2019] [Revised: 01/05/2020] [Accepted: 01/07/2020] [Indexed: 11/24/2022] Open
Abstract
The cell-of-origin of NPM1- and FLT3-mutated acute myeloid leukemia (AML) is still a matter of debate. Here, we combined in vitro clonogenic assays with targeted sequencing to gain further insights into the cell-of-origin of NPM1 and FLT3-ITD-mutated AML in diagnostic bone marrow (BM) from nine NPM1+/FLT3-ITD (+/−) AMLs. We reasoned that individually plucked colony forming units (CFUs) are clonal and reflect the progeny of a single stem/progenitor cell. NPM1 and FLT3-ITD mutations seen in the diagnostic blasts were found in only 2/95 and 1/57 individually plucked CFUs, suggesting that BM clonogenic myeloid progenitors in NPM1-mutated and NPM1/FLT3-ITD-mutated AML patients do not harbor such molecular lesions. This supports previous studies on NPM1 mutations as secondary mutations in AML, likely acquired in an expanded pool of committed myeloid progenitors, perhaps CD34−, in line with the CD34−/low phenotype of NPM1-mutated AMLs. This study has important implications on the cell-of-origin of NPM1+ AML, and reinforces that therapeutic targeting of either NPM1 or FLT3-ITD mutations might only have a transient clinical benefit in debulking the leukemia, but is unlikely to be curative since will not target the AML-initiating/preleukemic cells. The absence of NPM1 and FLT3-ITD mutations in normal clonogenic myeloid progenitors is in line with their absence in clonal hematopoiesis of indeterminate potential.
Collapse
Affiliation(s)
- Rafael Diaz de la Guardia
- Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, 08036 Barcelona, Spain; (R.D.d.l.G.); (B.L.-M.); (J.J.R.-S.); (M.L.B.); (C.B.)
| | - Laura González-Silva
- Instituto de Biomedicina y Biotecnología de Cantabria, Universidad de Cantabria-CSIC, 39011 Santander, Spain; (L.G.-S.); (I.V.)
| | - Belén López-Millán
- Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, 08036 Barcelona, Spain; (R.D.d.l.G.); (B.L.-M.); (J.J.R.-S.); (M.L.B.); (C.B.)
| | - Juan José Rodríguez-Sevilla
- Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, 08036 Barcelona, Spain; (R.D.d.l.G.); (B.L.-M.); (J.J.R.-S.); (M.L.B.); (C.B.)
| | - Matteo L. Baroni
- Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, 08036 Barcelona, Spain; (R.D.d.l.G.); (B.L.-M.); (J.J.R.-S.); (M.L.B.); (C.B.)
| | - Clara Bueno
- Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, 08036 Barcelona, Spain; (R.D.d.l.G.); (B.L.-M.); (J.J.R.-S.); (M.L.B.); (C.B.)
| | - Eduardo Anguita
- Hematology and hemotherapy Department, Hospital Clínico San Carlos, IMDL, IdISSC, Departamento de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain;
| | - Susana Vives
- Hematology Department, ICO-Hospital Germans Trias i Pujol, 08916 Badalona, Spain; (S.V.); (L.P.)
- Josep Carreras Leukemia Research Institute, Universitat Autònoma Barcelona, 08193 Barcelona, Spain
| | - Laura Palomo
- Hematology Department, ICO-Hospital Germans Trias i Pujol, 08916 Badalona, Spain; (S.V.); (L.P.)
- Josep Carreras Leukemia Research Institute, Universitat Autònoma Barcelona, 08193 Barcelona, Spain
| | - Helene Lapillonne
- Sorbonne Université, INSERM, Centre de recherche Saint-Antoine CRSA, AP-HP, Hôspital Armand Trousseau, Haematology Laboratory, F-75012 Paris, France;
| | - Ignacio Varela
- Instituto de Biomedicina y Biotecnología de Cantabria, Universidad de Cantabria-CSIC, 39011 Santander, Spain; (L.G.-S.); (I.V.)
| | - Pablo Menendez
- Department of Biomedicine, Josep Carreras Leukemia Research Institute, School of Medicine, University of Barcelona, 08036 Barcelona, Spain; (R.D.d.l.G.); (B.L.-M.); (J.J.R.-S.); (M.L.B.); (C.B.)
- Centro de Investigación Biomédica en Red de Cáncer (CIBER-ONC), ISCIII, 08036 Barcelona, Spain
- Instituciò Catalana de Recerca i Estudis Avançats (ICREA), Barcelona 08010, Spain
- Correspondence:
| |
Collapse
|